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Xanthohumol is the principal prenylated flavonoid of the female inflorescences of the hop
plant. In recent years, various beneficial xanthohumol effects including anti-inflammatory,
antioxidant, hypoglycemic activities, and anticancer effects have been revealed. This
review summarizes present studies indicating that xanthohumol also inhibits several
critical pathophysiological steps during the development and course of chronic liver
disease, including the activation and pro-fibrogenic genotype of hepatic stellate
cells. Also the various mechanism of action and molecular targets of the beneficial
xanthohumol effects will be described. Furthermore, the potential use of xanthohumol or
a xanthohumol-enriched hop extract as therapeutic agent to combat the progression of
chronic liver disease will be discussed. It is notable that in addition to its hepatoprotective
effects, xanthohumol also holds promise as a therapeutic agent for treating obesity,
dysregulation of glucose metabolism and other components of the metabolic syndrome
including hepatic steatosis. Thus, therapeutic xanthohumol application appears as a
promising strategy, particularly in obese patients, to inhibit the development as well as
the progression of non-alcoholic fatty liver disease.
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Introduction
Hop (Humulus lupulus L.) has been used since ancient times as a medicinal plant. Traditional
medicinal indications included the treatment of anxiety and insomnia, mild pain reduction or
combating dyspepsia (Zanoli and Zavatti, 2008). Today, hops are used in the manufacturing of
beer and female infertile plants are cultivated on high trolleys especially for brewing (Figure 1A).
Biologically active substances, which are also important for brewing, are concentrated inside hop
cones (Figure 1B) in lupulin glands (Figure 1C) which contain hop resins, bitter acids, essential
oils and prenylated flavonoids. These lupulin glands are tiny yellow sacs that are located at the base
of the petals of the hop cone (Figure 1D) that are found in female plants, while cones from the male
hop plant contain relatively few lupulin glands.
Xanthohumol (XN; 3′-[3,3-dimethyl allyl]-2′,4′,4-trihydroxy-6′-methoxychalcone) is the
principal prenylated chalcone of the hop plant (Figure 1E). The yellow compound (Greek:
Abbreviations: BW, body weight; ECM, extracellular matrix; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HSC,
hepatic stellate cells; IFN, interferon; MS, metabolic syndrome; NF-κB, nuclear factor-κB; XN, xanthohumol.
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FIGURE 1 | Hop plant and xanthohumol. (A) Hop plant (Humulus
lupulus) field in Bavaria, showing the typical form of cultivation on high
trolleys. (B) Female hop flowers (hop cones), where the biologically
active substances, which are also important for brewing, are
concentrated inside in the lupulin glands; (C) lupulin glands, which
contain hop resins, bitter acids, essential oils and prenylated flavonoids.
(D) Schematic drawing of a female hop cone that is composed of a
central spine (i.e., the strig), bracts (i.e., pear-shaped petal that does
not contain lupulin glands), bracteoles (i.e., pear-shaped petal of the
hop cone that shelters the lupulin glands and any seeds that may be
present), and the characteristic lupulin glands that are tiny yellow sacs
containing the hop oils. (E) Chemical structure of xanthohumol
(3′-[3,3-dimethyl allyl]-2′,4′,4-trihydroxy-6′-methoxychalcone), the major
prenylated chalcone of the hop plant.
xantho = yellow) is found in high quantities in the lupulin
glands. Since the 1990s, interest in health-promoting activities of
XN increased constantly, scientific investigations were initialized
worldwide and papers and patents on this topic have increased
steadily (Gerhauser and Frank, 2005).
Many studies identified XN as a broad-spectrum cancer
chemopreventive agent acting by multiple mechanisms relevant
for cancer development and progression (Gerhauser et al.,
2002). XN is able to scavenge reactive oxygen species and it
modulates many enzymes involved in carcinogen metabolism
and detoxification (Gerhauser et al., 2002). Furthermore, XN
inhibits cyclooxygenase 2 (COX-2) expression and the activity
of both Cox-1 and Cox-2 in lipopolysaccharide-mediated iNOS
induction in the macrophages (Stevens and Page, 2004). XN also
has been shown to decrease prostaglandin-E2 (PGE2) expression
(Jongthawin et al., 2012). These anti-inflammatory properties
may contribute to the inhibition of tumor promotion by the
inhibition of nuclear factor-κB (NF-κB) signaling and subsequent
down-regulation of pro-inflammatory factors (Albini et al.,
2006; Colgate et al., 2007). Moreover, estrogen-mediated tumor
promotion may be prevented by XN, which suppresses estrogen-
signaling through the inhibition of the interaction between the
oncoprotein brefeldin A-inhibited guanine nucleotide-exchange
protein 3 (BIG3) and tumor suppressor prohibitin 2 (PHB2)
(Yoshimaru et al., 2014). XN also inhibits the enzyme aromatase
(CYP19), which plays a crucial role in the conversion of
testosterone to estrogen (Monteiro et al., 2006). Furthermore,
XN inhibits tumor cell growth by different mechanism such as
decrease of DNA polymerase alpha activity and inhibition of
DNA synthesis (Gerhauser et al., 2002). Moreover, XN induces
apoptosis by poly(ADP-ribose)polymerase (PARP) cleavage,
activation of caspases or down-regulation of Bcl-2 protein
expression (Pan et al., 2005). XN has further been shown to
modulate drug metabolism in vitro by inhibition of various
Cyp enzymes and by induction of quinone reductase activity
(Henderson et al., 2000; Miranda et al., 2000a), which has
been considered as a biomarker for cancer chemoprevention
(Cuendet et al., 2006). In addition to the molecular mechanism
by which XN affects cancer cells, it has been shown to exhibit
several further biological effects (Figure 2) which are also
playing an important role during the course of chronic liver
disease. Hepatic fibrosis is the peril that determines morbidity
and mortality in patients with liver disease. Cirrhosis, as the
end stage of hepatic fibrosis, is a major clinical issue for its
high prevalence in the world and its tight relationship with
hepatocellular carcinoma (HCC) incidence (Gines et al., 2004;
Villanueva et al., 2007; Minguez et al., 2009). The activation of
hepatic stellate cells (HSC) is the key event of hepatic fibrosis
(Lang and Brenner, 1999; Kisseleva and Brenner, 2007; Elpek,
2014). Activated HSC/myofibroblasts are the cellular source
of the excessive extracellular matrix (ECM) deposition (Lang
and Brenner, 1999; Kisseleva and Brenner, 2007). Furthermore,
activated HSC/myofibroblasts form and infiltrate the tumor
stroma and promote HCC progression (Amann et al., 2009).
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FIGURE 2 | Biological effects of xanthohumol. Xanthohumol (XN) has
been shown to have wide spectrum of biological effects, by which it may also
affect different pathophysiological mechanisms involved in the development
and progression of chronic liver disease. Studies have shown that XN acts
anti-angiogenic (Albini et al., 2006; Shamoto et al., 2013), anti-carcinogenic
(Dorn et al., 2010a,b,c; Araujo et al., 2011), chemopreventive (Miranda et al.,
2000c; Gerhauser et al., 2002; Dorn et al., 2010a), anti-microbial (Gerhauser
and Frank, 2005; Rozalski et al., 2013; Kramer et al., 2015), anti-viral
(Buckwold et al., 2004; Zhang et al., 2009, 2010; Lou et al., 2014),
anti-inflammatoric (Dorn et al., 2010a, 2013; Jongthawin et al., 2012), as a
ROS scavenger (Gerhauser et al., 2002), anti-diabetic (Legette et al., 2013),
and anti-oxidative (Gerhauser et al., 2002). In regard to liver fibrogenesis, it
was shown that XN has anti-fibrogenic potential (Dorn et al., 2010a, 2013;
Yang et al., 2013) and inhibits HSC activation and proliferation (Dorn et al.,
2010a). Moreover, XN improves the metabolic syndrome (Legette et al.,
2013).
Therefore, these cells are a critical target for therapy during the
whole course of chronic liver disease. However, up to date, no
effective therapy is available to block the activation of HSC or
to inhibit the pro-inflammatory and pro-fibrogenic activity of
the activated HSC. In the following, we provide a summary of
present studies indicating the potential of this hop constituent as
a therapeutic agent to beneficially affect hepatic fibrosis as well
as various further pathological mechanisms during the course of
chronic liver disease.
Effects of Xanthohumol on Hepatic Stellate
Cells in vitro
As already mentioned, the activation of HSC plays a critical
pathophysiological role in the progression of chronic liver disease
and the activation of these cells in response to liver injury is
considered as the key event of hepatic fibrosis (Bataller and
Brenner, 2001). Interestingly, XN has been shown to inhibit the
activation of primary human HSC in vitro in concentrations
as low as 5µM XN (Dorn et al., 2010a). Furthermore, XN
induced apoptosis in activated HSC in vitro in a dose-dependent
manner (0–20µM). Moreover, XN reduced expression of the
pro-inflammatory factors such as the monocyte chemoattractant
protein-1 (MCP-1) or pro-fibrogenic genes such as type I
collagen in HSC. MCP-1 is regulated by NF-κB and increased
levels are associated with fibrosis progression in chronic liver
disease (Jarrar et al., 2008; Wouters et al., 2008). Further, NF-
κB activation is a central pathophysiological mechanism during
HSC activation (Hellerbrand et al., 1998a,b; Elsharkawy et al.,
2005). Importantly, XN inhibited NF-κB activity in activated
HSC in vitro (Dorn et al., 2010a). In summary, in vitro studies
revealed that XN inhibits several key pathological factors of
HSC activation and their contribution to fibrosis progression in
chronic liver disease (Figure 3). In addition, XN has been shown
to inhibit HSC-activation and hepatic fibrosis in experimental
models of liver injury (please see below). Future research, may
aim at the identification of further molecular pathways which
may contribute to the anti-fibrogenic effect of XN in HSC.
Anti-viral and Antimicrobial Activities of XN
HSC activation occurs in response to hepatocellular injury, and
hepatitis C virus (HCV) infection is a one of the major causes
of liver infectious diseases. In vitro studies using virus that
causes bovine diarrhea (bovine viral diarrhea virus - BVDV
E2), which shows considerable similarities with the human
HCV, showed that XN inhibits BVDV replication and enhanced
the anti-viral activity of interferon (IFN)-α (Buckwold et al.,
2004; Zhang et al., 2009, 2010). Antiviral activity of XN in
combination with IFNα-2b, was also demonstrated against
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FIGURE 3 | Reported in vitro effects of xanthohumol in hepatic
stellate cells. Xanthohumol (XN) inhibits the activation of hepatic stellate
cells (HSC) as well as several key pathological factors of activated HSC
including pro-inflammatory and -fibrogenic gene expression, proliferation,
apoptosis resistance, and composition of extracellular matrix. In particular, it
is known that XN inhibits pro-inflammatory and pro-fibrogenic (Dorn et al.,
2010a, 2013) gene expression and HSC activation (Yang et al., 2013)
thereby preventing the excessive formation and deposition of extracellular
matrix as well as the activation and proliferation of HSC. In addition, XN was
shown to interfere with HSC apoptosis (Dorn et al., 2010a).
herpes simplex virus and cytomegalovirus (Buckwold et al.,
2004). More recently, XN was examined for its ability to inhibit
HCV virus replication in a cell culture system carrying replicating
HCV RNA replicon and it was shown that XN has similar
inhibitory effects as IFNα-2b (Lou et al., 2014). Bacteria and
bacterial translocation from the intestine have been shown to
promote the progression of chronic liver disease, including HSC-
activation and fibrogenesis (Seki et al., 2007). More recently,
it has been shown that antibiotics improved the intestinal
permeability and attenuated liver fibrosis development associated
with Nonalcoholic Steatohepatitis (NASH) via the inhibition
of HSC activation (Douhara et al., 2015). With regards to
this, it is important, that the broad spectrum of antimicrobial
activity of XN is well known (Gerhauser, 2005). More recently,
the inhibitory effect of a hop extract containing XN was
demonstrated against different gram-positive bacteria including
Listeria monocytogenes and Staphylococcus aureus (Kramer et al.,
2015).
In summary, there is a high rationale that XN may exhibit
beneficial effects in liver disease also via inhibiting bacterial
translocation or the growth of (gram-positive) bacteria. Still
experimental proof of this hypothesis is missing, which may be
the subject of future research in appropriate (in vivo) models or
clinical studies.
XN Effects on Hepatocellular Cancer Cells
and Primary Hepatocytes
As already mentioned, a number of studies indicated the
potential of XN to prevent and treat different types of cancers
(Araujo et al., 2011). In the pathogenesis of HCC, XN
exhibited anti-tumorous effects and induced the apoptosis in
two different human HCC cell lines (HepG2 and Huh7) in vitro
at concentration of 25µM (Dorn et al., 2010b). Furthermore,
XN repressed proliferation and migration in both cell lines even
at lower concentrations (Dorn et al., 2010a). In a study with
HepG2 cells, anti-mutagenic effects of XN were demonstrated
even at concentrations of 0.01–0.1µM (Plazar et al., 2008;
Viegas et al., 2012). Chemopreventative effects can also occur by
detoxifying carcinogens through the action of specific enzymes.
One of these enzymes is NAD(P)H: quinone reductase that
catalyzes the reduction of quinone to hydroquinones, which
are more suitable substrates for subsequent conjugation. It was
found that XN increased by several fold the activity of quinone
reductase in murine liver cells (Hepa-1c1c7) (Miranda et al.,
2000b) at concentrations above 1µM. Importantly, even at XN
concentrations as high as 100µM, XN did not affect the viability
of primary human hepatocytes in vitro (Dorn et al., 2010a).
It should be noted that in cellular experiments performed with
XN the reproducibility of all these findings might be affected by
the low solubility of XN in cell culture medium, the composition
of media used, the tendency of XN to absorb to various plastic
materials routinely used in the cell culture, and the reduction
of the effective XN dose by conversion to isoxanthohumol
(Motyl et al., 2012). Likewise, the bioavailability of XN and its
prenylated flavanone (i.e., Isoxanthohumol) is marked by inter-
individual variability that is induced by variations in the intestinal
microbial community and their degradation pathways that have
direct impact on biotransformation of respective compounds
(Possemiers et al., 2005).
Therefore, studies that investigate pharmacological effects of
XN or its natural or synthetic derivatives should punctiliously
describe all details of the chosen experimental setting, not
only including sources and concentrations of employed
prenylflavonoid but also specification of media and buffer
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composition, identity and origin of cell lines and animals, details
about culture conditions, animal accommodation, supplier of
plastic ware, and many others.
Furthermore, future research may focus on the identification
of (downstream) signaling pathways responsible for
xanthohumol effects in hepatocytes. Recently, it has been
shown that the activation of Nrf2 pathway and subsequently
phase II enzymes in concert with p53 induction may account
for the molecular mechanism of the chemopreventive activity
of XN in hepatocytes (Krajka-Kuzniak et al., 2013). On the
other hand its cytotoxicity toward HCC cells indicates that
it may also be considered as potentially chemotherapeutic
(Dorn et al., 2010a). Moreover, the antimutagenic effects of
XN were demonstrated against various procarcinogens, which
are activated by cytochrome P450 enzymes (Plazar et al., 2007;
Ferk et al., 2010). The mechanisms are possibly related to the
inhibition of the metabolic activation by human cytochrome
P450 1A2 (CYP1A2) and inhibition of the binding of the
metabolites to DNA and proteins (Miranda et al., 2000c).
Moreover, XN interferes with several stages in the angiogenic
process, including inhibition of endothelial cell invasion and
migration, growth, and formation of tubular-like structures
(Gerhauser et al., 2002; Albini et al., 2006). The mechanisms for
its inhibition of angiogenesis are related to the blockage of both
the nuclear factor-κB (NFκB) and Akt pathways in endothelial
cells (Albini et al., 2006). Furthermore, in addition to the direct
effect of XN on the vascular cells, XN inhibits the production
of angiogenic factors, e.g., vascular endothelial growth factor
(VEGF) and interleukin 8 (IL-8) via the inhibition of NF-κB
(Shamoto et al., 2013). Still, according analyses in primary
hepatocytes are missing.
XN Effects in Models of Acute Liver Injury
There is already a multitude of reports describing beneficial
effects of XN on liver injury in vitro and in vivo (Table 1).
Hepatic ischemia/reperfusion (I/R) injury occurs in a variety
of clinical scenarios, including transplantation, liver resection,
trauma, and hypovolemic shock. The process of hepatic I/R-
injury can be divided into two phases; an acute phase (the first
6 h after reperfusion) and the following sub-acute phase (Fan
et al., 1999). The acute phase is characterized by generation of
reactive oxygen species (ROS) subsequent to reoxygenation of
the liver leading to marked hepatocellular damage (Parks and
Granger, 1988; Rauen et al., 1994). Noteworthy, pretreatment of
mice with XN (1,000mg/kg body weight for 5 days) significantly
ameliorated I/R-induced oxidative stress 6 h after reperfusion
(Dorn et al., 2013). Although hepatocellular damage was not
modulated at this early phase, the I/R-induced NF-κB activation
and pro-inflammatory gene expression was almost completely
blunted (Dorn et al., 2013). These factors play a crucial role in the
later course of hepatic I/R-injury via recruitment and activation
of pro-inflammatory cells (Jaeschke et al., 1992; Jaeschke, 1996).
Also in an ex vivo-model of cold hepatic I/R XN revealed an
antioxidant and inhibitory effect on NF-κB activity (Hartkorn
et al., 2009).
The liver is also frequently exposed to various insults,
including toxic chemicals (Zimmerman and Lewis, 1995;
Grunhage et al., 2003). Liver damage caused by hepatotoxic
chemicals induces liver necrosis due to direct damage of
hepatocytes and subsequent inflammation (Mehendale et al.,
1994). Carbon tetrachloride (CCl4), an industrial solvent, is
a hepatotoxic agent and its administration is widely used as
an animal model of toxin-induced liver injury that allows
the evaluation of both necrosis and subsequent inflammation
(Huh et al., 2004) as well as fibrosis (Iredale, 2007). In this
model, oral application of XN (500mg/kg BW) was shown to
significantly inhibit the pro-inflammatory and pro-fibrogenic
hepatic gene expression (Dorn et al., 2012). Noteworthy, these
effects occurred despite the fact that hepatocellular injury as
reflected by serum levels of transaminases or histomorphological
analysis was comparable between control mice and XN-fed mice.
These findings suggest that the suppressive effect of XN against
the progress of acute CCl4-induced hepatic fibrosis involved
direct mechanisms related to its ability to block both hepatic
inflammation and the activation of HSC.
In summary, these findings indicate the potential of XN to
exhibit a beneficial effect in acute liver injury or failure. Still, it
has to be mentioned that in the studies cited above XN has be
applied before the onset of liver injury, i.e., prevented acute liver
injury in experimental models. Further studies are warranted to
analyzed the therapeutic potential of XN, i.e., after the onset of
liver injury. A further potential clinical application of XN might
be the prevention of oxidative stress in conservation solutions
during the organ transplantation process. However, also here,
future studies are warranted.
Effect of XN in Models of Chronic Liver
Injury
Chronic HCV infection is one of the most frequent liver diseases
worldwide (Yang et al., 2013). In an elegant study, Yang et al.
analyzed the hepatoprotective effect of XN in an in vivo model
of HCV infected Tupaias. XN was applied by gavage at a
dose of 100mg/kg BW which led to a significant reduction of
hepatic inflammation and fibrosis compared to control animals.
Interestingly, XN also inhibited the hepatic steatosis in this
model, which was found to be related to an inhibitory effect on
microsomal triglyceride transfer protein activity and inhibition
of hematopoietic stem cells (Yang et al., 2013).
Besides alcohol abuse, non-alcoholic fatty liver disease
(NAFLD) has emerged as the most frequent liver disease in
Western countries (Clark et al., 2002; Cobbold et al., 2010;
Vernon et al., 2011). Today, the metabolic syndrome (MS)
is one of the major public health challenges worldwide that
is characterized by clustering of waist circumference, blood
triglycerides, high density lipoprotein (HDL) cholesterol and
fasting glucose levels. MS is also closely associated with NAFLD,
and thus today, NAFLD is considered as a component of the
MS (reviewed in Saidijam et al., 2014). MS affects approximately
25 per cent of the adult population in Western countries and
also is quickly increasing in young populations. Accordingly, also
NAFLD incidence is further increasing and effective strategies
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TABLE 1 | Beneficial effects of Xanthohumol on liver injury.
Finding made in Model Biological activity References
In vitro (cell culture
model)
Hepatitis C virus replication in cell culture XN reduced hepatitis C virus RNA levels Lou et al., 2014
Cultivated human hepatocytes and hepatic stellate
cells
In both cell types XN inhibited activation of the transcription factor
NF-κB and expression of NF-κB dependent proinflammatory
genes
Dorn et al., 2010a
Hepatocellular carcinoma cell lines (HepG2 and
Huh7)
XN induced apoptosis and repressed proliferation and migration
as well as TNF-induced NF-κB activity
Dorn et al., 2010b
Comet assay in cultured human hepatoma cell line
HepG2
XN prevents the formation of DNA strand breaks, indicating that its
protective effect is mediated by induction of cellular defense
mechanisms against oxidative stress
Plazar et al., 2007
In vitro (Precision
cut liver slices)
Precision-cut rat liver slices XN completely prevented
2-amino-3-methylimidazo[4,5-f]quinoline- and
benzo(a)pyrene-induced DNA damage
Plazar et al., 2008
In vivo (mice) Ischemia-reperfusion (I/R) induced liver injury in
BALB/c mice
Orally applied XN (1 mg/g body weight for 5 days before I/R-injury)
reduced liver injury, NF-κB activation, expression of
proinflammatory cytokines
Rauen et al., 1994
Carbon tetrachloride-induced acute liver injury in 10
weeks old female BALB/c mice
XN inhibited pro-inflammatory and profibrogenic hepatic gene
expression and decreased hepatic NF-κB activity
Dorn et al., 2012
Western-type diet-fed ApoE-deficient mice XN reduced plasma cholesterol concentrations, decreased
atherosclerotic lesion area, and attenuated plasma concentrations
of the proinflammatory cytokine monocyte chemoattractant
protein 1
Doddapattar et al.,
2013
Mouse model of Non-Alcoholic Steatosis XN reduced hepatic inflammation and expression of profibrogenic
genes
Dorn et al., 2010a
In vivo (Tupaia) Hepatitis C virus infected Tupaia belangeri XN improves hepatic inflammation, steatosis and fibrosis through
inhibition of oxidative reaction and regulation of apoptosis and
suppression of hepatic stellate cell activation
Yang et al., 2013
In vivo (rat) High fat diet in rats XN inhibited the increase of body weight, liver weight, and
triacylglycerol levels
Yui et al., 2014
Orally administered hop extract and subcutaneously
injection of XN in Sprague-Dawley rats over 4 days
XN display cytoprotective effects in the liver Dietz et al., 2013
Carbon tetrachloride-induced acute liver injury in
rats
XN evolves hepatoprotective effects by its antioxidant properties
and inhibition of lipid peroxidation and degradation of antioxidant
enzymes that are induced by CCl4 intoxication
Pinto et al., 2012
Metabolic syndrome in 4 week old Zucker fa/fa rats XN has beneficial effects on markers of metabolic syndrome such
as body weight and plasma glucose levels
Legette et al.,
2013
Amino-3-methyl-imidazo[4,5-f ]quinoline-induced
preneoplastic foci formation in rat livers
XN protects against DNA damage and cancer Pinto et al., 2012
IR-induced hepatic injury in rats XN reduced reactive oxygen species formation and NF-κB activity
in vitro and lipid peroxidation was attenuated, while Bcl-X
expression and caspase-3 like activity was decreased
Hartkorn et al.,
2009
Abbreviations used are: I/R, Ischemia-reperfusion; NF-κB, nuclear factor-κB; XN, Xanthohumol.
to prevent the development and progression of NAFLD to its
advanced form NASH are urgently needed. Of note, XN has
been shown to exhibit a beneficial effect in different experimental
NAFLD models. Yui et al. reported that feeding rats a high-fat
diet enriched with XN extract (1% w/w equivalent to a dose of
100mg/kg BW) inhibited the increase of body and liver weight,
as well as triacylglycerol levels in the plasma and in the liver
(Yui et al., 2014). The mechanisms were found to be related
to the regulation of the hepatic fatty acid metabolism and an
inhibition of fat absorption in the intestine (Doddapattar et al.,
2013). In this study, XN also tended to reduce hepatic fatty
acid synthesis through the reduction of hepatic sterol regulatory
element-binding protein (SREBP) 1c mRNA expression in rats
fed with a high-fat diet. Furthermore, it was observed that plasma
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adiponectin levels tended to be elevated by dietary application
of the XN-rich hop extract (Yui et al., 2014). Also in a second
model, in which NASH was induced by feeding the mice with
an NASH-inducing diet, XN exhibited anti-inflammatory and
anti-fibrogenic effects (Dorn et al., 2010a). Here, XN was applied
in the diet in a concentration of 1% W/W corresponding to a
dose of approximately 1000mg/kg BW. In this model, after 3
weeks feeding, the induction of hepatic inflammation and pro-
fibrogenic gene expression was almost completely blunted in
mice receiving XN-supplemented NASH diet compared to mice
fed with the pure NASH-diet (Dorn et al., 2010a).
Moreover, ApoE−/− mice showed decreased hepatic
triglyceride and cholesterol content, activation of AMP-activated
protein kinase, phosphorylation and inactivation of acetyl-CoA
carboxylase, and reduced expression levels of mature SREBP-1c
upon 8 weeks XN feeding (300mg/kg BW/day) (Doddapattar
et al., 2013).
In summary, XN has been shown to beneficially affect
several components of the metabolic syndrome. Furthermore,
it positively affects other obesity associated pathological factors
such as misbalance of adipokine levels, which are known
to promote NAFLD development and progression. Fitting
to this is the beneficial effect of XN on hepatic steatosis,
inflammation and fibrosis in experimental NASH models. In
addition to NAFLD/NASH, XN revealed positive effects in other
experimental models of chronic liver injury such as HCV, which
can be explained by the above described inhibitory effects on
fibrogenic and inflammatory gene expression or anti-bacterial
effects. Still, it has to be noted that in the published studies, XN
was applied in a preventive experimental setting. Future studies
are warranted to analyze the potential of XN to treat, i.e., stop or
reverse liver fibrosis.
Pharmacokinetics and Effective Dose
of XN
Recent studies enhanced our knowledge regarding metabolisms
and pharmacokinetics of XN (Nookandeh et al., 2004; Legette
et al., 2012, 2014). Investigations using human liver microsomes
showed that the hydroxylation of a prenyl methyl group is
the primary route of the oxidative metabolism. Furthermore,
XN and its metabolites were found to be excreted mainly in
feces within 24 h of administration, when XN was fed to rats
up to a dose of 500mg/kg BW (Avula et al., 2004; Hanske
et al., 2010). Twenty two metabolites were identified in the
feces, most of them confined to modified chalcone structures
and flavanone derivatives (Nookandeh et al., 2004). Still, most
of the XN remained unchanged in the intestinal tract (89%),
and only 11% were found to be metabolites (Nookandeh
et al., 2004). Furthermore, two phase I metabolites and five
phase II metabolites were identified in rats revealing oxidation,
demethylation, hydration and sulfatation reactions (Jirasko et al.,
2010). The bioavailability of XN in rats was found to be
dose-dependent (0.33, 0.13, and 0.11) upon oral administration
of single XN doses (1.86, 5.64, and 16.9mg/kg BW) (Legette et al.,
2012).
Despite the poor bioavailability, the highest XN
concentrations are reached in intestinal cells and non-
parenchymal liver cells upon oral uptake. Here, the anatomical
situation of the liver has to be considered. Thus, it can be
expected, that after oral intake of XN its concentration in the
portal vein is higher than in the systemic circulation. Further,
HSC are located in the liver in the space of Disse (perisinusoidal
space), i.e., between the sinusoids and the hepatocytes. Herewith,
HSC are directly exposed to XN concentration reaching the liver
via the portal vein irrespective of the (subsequent) metabolism
in hepatocytes. Anti-fibrogenic effects have been observed at
concentrations as low as 5µM (Dorn et al., 2010a), and in
previous studies we found that these concentration levels are
reached in the murine hepatic tissue upon oral administration of
XN at dose of 1000mg/kg BW (Dorn et al., 2013). Furthermore,
it has to be considered that XN concentrations reaching HSC in
the space between the endothelial cells and the hepatocytes (i.e.,
space of Disse) likely are significantly higher than the levels in
whole liver tissue.
Still, the applied dose of 1000mg/kg BW in this study (Dorn
et al., 2013) was quite high and it has not yet been exactly
defined what XN doses are required to achieve hepatoprotective
effects. In the above described studies revealing beneficial effects
in models of acute and chronic liver injury, XN was applied
in the dose-range of approximately 100–1000mg XN/kg BW to
mice and rats. Effective doses with regards to beneficial effects on
other components of the metabolic syndrome were achieved with
doses in the range of 15–300mg XN /kg BW in rats and mice
(Doddapattar et al., 2013; Legette et al., 2013; Yang et al., 2013;
Yui et al., 2014). In addition, there are several further studies
in other experimental disease models, which revealed beneficial
effects in doses as low as 0.2–9mg XN/kg BW (Benelli et al., 2012;
Negrao et al., 2012; Rudzitis-Auth et al., 2012; Yen et al., 2012;
Costa et al., 2013). For example, Costa et al. have shown that XN
modulates inflammation, oxidative stress, and angiogenesis in a
type 1 diabetic rat skin wound healing model by supplementing a
stout beer with 10mg XN/L, which corresponds to approximately
1mg XN/kg BW/day (Costa et al., 2013). Moreover, Benelli et al.
reported that XN revealed beneficial effects in a murine model of
leukemia in doses as low as 2mg XN/kg BW (Benelli et al., 2012).
Potential Forms of XN Application
Elegant studies by Legette et al. (2012) demonstrated
the similarity of XN metabolisms and pharmacokinetics
between rodents and humans, which allows the translation
of data generated in murine and rat models into clinical
studies/application. To convert an animal dose (mg/kg BW) to
the human equivalent dose (HED), the murine dose should be
either divided by 12.3 or multiplied by 0.08. Oral dose ratio can
be calculated using allometric interspecies scaling 1.
1Guidance for Industry, Estimating the maximum safe starting dose in
initial clinical trials for therapeutics in adult healthy volunteers. This
guidance can be downloaded at http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM078932.pdf (last
downloaded March 20, 2015).
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For humans, beer is the major dietary source of XN. The
beer content of XN varies significantly depending on the type
of beer (in the range of 0.052–0.628mg/l) (Chen et al., 2010).
Lager and Pilsener beers have fairly low levels of this compound,
and the highest levels of XN are found in Stout or Porte
(Stevens et al., 1999). Moreover, it was possible to produce a
dark beer enriched in XN (3.5mg/l) (Magalhães et al., 2008),
and a brewing process has been developed that produces a
beer that contains 10 times the amount of XN as traditional
brews (Wunderlich et al., 2005). Even upon consumption of such
special types of beer, a daily beer consumption of approximately
150–1500 l would be necessary by a man (75 kg) to reach doses
corresponding to 100–1000mg XN/kg BW/day in mice, i.e.,
doses which have been shown to exhibit hepatoprotective effects.
Thus, with regards to hepatoprotective effects, pharmacologically
relevant XN concentrations cannot be reached in men by beer
consumption. Moreover, there is certainly unanimous hesitancy
among researchers to recommend drinking alcohol to avoid any
kind of disease because of the fine line between moderate and
binge drinking. Certainly, this is evenmore true in case of chronic
liver disease.
However, XN can also be isolated from hops in large
quantities, and different methods (e.g., extraction via liquid
supercritical carbon dioxide) were developed to isolate XN
from hop cones in large quantities. Thus, independent of
beer intake, XN may be used as hepatoprotective dietary
supplement. Therefore, pharmacological relevant concentrations
can be reached by oral administration of XN enriched
functional food, e.g., XN enriched beverages or solid foods.
Methods or formulations for increasing the water solubility and
bioavailability are presently object of numerous national or global
patents2).
2International application published under the patent cooperation
treaty (PCT). A representative example can be downloaded at
Safety of XN Application
One prerequisite for therapeutic application is the good safety
profile of the used agent. Especially hepatotoxic properties have
to be excluded, when the therapeutic agent must be taken by
patients with liver disease. Hop has a long history as a medicinal
plant and is known for its good tolerance. More recently, we and
others have confirmed the safety of oral application of XN and
XN-enriched hop extracts in rats and mice. Oral administration
of XN (700mg/kg/day BW) to mice for 4 weeks did neither affect
the major organ functions, nor the protein, lipid, or carbohydrate
metabolism (Vanhoecke et al., 2005). Similarly, mice fed with
a XN enriched diet (1000mg/kg BW) for 3 weeks exhibited no
adverse effects (Dorn et al., 2010a). Histopathological evaluation
of major organs (liver, kidney, colon, lung, heart, spleen, and
thymus) as well as biochemical serum analysis, confirmed that
XN did not negatively affect organ function and homoeostasis
(Dorn et al., 2010c). Most recently, first in man studies confirmed
the safety and good tolerability of XN or XN-enriched hop
extracts, respectively. An escalating dose study (up to 1.35mg
XN/kg BW/day for 1 week) in menopausal women revealed that
the XN enriched extract did neither affect the serum levels of
sex hormones nor blood clotting. Also no other side effects were
observed (van Breemen et al., 2014). A further study confirmed
the safety of oral administration of a single XN dose (160 mg,
i.e., approximately 2.5mg XN/kg BW/day) in healthy volunteers
(Legette et al., 2014).
Summary and Conclusion
In vitro and in vivo data indicate that the hop constituent
xanthohumol (XN) affects several critical pathophysiological
steps during the development and course of chronic liver disease,
http://www.lens.org/images/patent/WO/2007016578/A2/WO_2007_016578_A2.
pdf (last downloaded March 20, 2015).
FIGURE 4 | Xanthohumol effects on different pathophysiological
factors during the course of non-alcoholic fatty liver disease.
Xanthohumol (XN) has the potential to inhibit hepatic steatosis, inflammation,
fibrosis and even the causes of liver injury by interaction on different levels,
i.e., pathogenesis of steatosis (Dorn et al., 2010a; Doddapattar et al., 2013;
Yang et al., 2013; Yui et al., 2014), inflammation (Dorn et al., 2010a, 2013;
Yang et al., 2013), fibrosis (Dorn et al., 2010a, 2013; Yang et al., 2013), and
cancerogenesis (Gerhauser et al., 2002; Dorn et al., 2010b).
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including hepatic inflammation and fibrosis, as well as the
formation and progression of liver cancer (Figure 4). Also on
the molecular level, XN ameliorates several mechanisms which
play a critical role in the pathogenesis of acute and chronic
liver injury. Strikingly, inhibitory XN effects on activated hepatic
stellate cells (HSC)/myofibrobasts take place in a concentration
range, which is significantly lower than the concentration
which is shown to be safe for primary human hepatocytes
in vitro. Furthermore, upon oral application, HSC are exposed
to relatively high XN concentrations due to their location in
the space of Disse irrespective of the hepatic metabolisms. This
indicates these non-parenchymal liver cells as attractive targets
for therapeutic XN application. Of note, XN also holds promise
as a therapeutic agent for treating obesity, dysregulation of
glucose metabolism and other components of the metabolic
syndrome including hepatic steatosis. Thus, therapeutic XN
application appears as promising strategy, particularly in obese
patients, to inhibit the development as well as the progression of
NAFLD.
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